Results of maintenance treatment of recurrent and metastatic colorectal cancer with capecitabine with or without bevacizumab
Main Article Content
Abstract
This study aimed to evaluate the outcomes of maintenance treatment for recurrent and metastatic colorectal cancer (CRC) using capecitabine with or without bevacizumab. An observational longitudinal study was conducted on 84 CRC patients at K Hospital from October 2022 to February 2025. Patients received an average of 9.6 treatment cycles. The median treatment duration was 7.8 months (range: 2.4 - 22.8 months), and the median progression-free survival (PFS) for maintenance therapy was 10.9 months. PFS was 11.9 months in the maintenance treatment group with bevacizumab and 7.8 months in the group without bevacizumab (p = 0.02). Patients who achieved a response to first-line treatment exhibited a longer median PFS compared to those with stable disease, with median durations of 11.8 months and 6.9 months, respectively (p = 0.02). The median PFS among patients with peritoneal metastases was 7.9 months, whereas it was 11.5 months in those without peritoneal metastases (p = 0.04).
Article Details
Keywords
Maintenance therapy, recurrent colorectal cancer, metastasis, capecitabine, bevacizumab
References
2. Daly MC, Paquette IM. Surveillance, Epidemiology, and End Results (SEER) and SEER-Medicare Databases: Use in Clinical Research for Improving Colorectal Cancer Outcomes. Clin Colon Rectal Surg. 2019;32(1):61-68. doi:10.1055/s-0038-1673355
3. De Falco V, Napolitano S, Roselló S, et al. How we treat metastatic colorectal cancer. ESMO Open. 2020;4(Suppl 2):e000813. doi:10.1136/esmoopen-2020-000813
4. Sonbol MB, Mountjoy LJ, Firwana B, et al. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. JAMA Oncol. 2020;6(3):e194489. doi:10.1001/jamaoncol.2019.4489
5. Morris VK, Kennedy EB, Baxter NN, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023;41(3):678-700. doi:10.1200/JCO.22.01690
6. Luo HY, Li YH, Wang W, et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(6):1074-1081. doi:10.1093/annonc/mdw101
7. Simkens LHJ, Tinteren H van, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. The Lancet. 2015;385(9980):1843-1852. doi:10.1016/S0140-6736(14)62004-3
8. Hoàng Thị Cúc, Trần Thắng, Hoàng Ngọc Tấn. Hiệu quả của capecitabine đơn chất trong điều trị duy trì ung thư đại trực tràng di căn tai bệnh viện K. Tạp chí Y học Việt Nam. 2022;515(1).
9. Trần Thị Thuý, Vũ Hồng Thăng, Hoàng Thị Cúc. Kết quả điều trị duy trì capecitabine kết hợp bevacizumab trên bệnh nhân ung thư đại trực tràng giai đoạn muộn. Tạp chí Ung thư học. 2020;1.
10. Yalcin S, Uslu R, Dane F, et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III “Stop and Go” study results--a Turkish Oncology Group Trial. Oncology. 2013;85(6):328-335. doi:10.1159/000355914
11. Richard A A, David J F, Janet G, et al. Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. J Clin Oncol. 2021 Nov 20;39(33):3693-3704. doi: 10.1200/JCO.21.01436
12. Huang W, Zhang H, Tian Y, et al. Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer. J Clin Pharm Ther. 2022;47(4):531-538. doi:10.1111/jcpt.13576
13. Aparicio T, Ghiringhelli F, Boige V, et al. Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(7):674-681. doi:10.1200/JCO.2017.75.2931
14. Díaz-Rubio E, Gómez-España A, Massutí B, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. The Oncologist. 2012;17(1):15-25. doi:10.1634/theoncologist.2011-0249
15. D K, Dc B, R von M, et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol Off J Eur Soc Med Oncol. 2015;26(4). doi:10.1093/annonc/mdv011